HLA Testing is NOT Indicated in Intracerebral Hemorrhage
HLA (human leukocyte antigen) testing should not be performed in patients with intracerebral hemorrhage (ICH), as it has no role in the diagnosis, acute management, or treatment of this condition.
Why HLA Testing is Not Relevant to ICH
HLA testing is used in hematology for stem cell transplantation matching and managing platelet refractoriness 1, but has no application in stroke care. The comprehensive guidelines from the American Heart Association/American Stroke Association 2, 3 and Canadian Stroke Best Practice recommendations 4 provide detailed protocols for ICH evaluation and management—none include HLA testing.
What Testing IS Actually Needed in ICH
Instead of HLA testing, the initial assessment of ICH patients requires:
Immediate Imaging Studies
- CT or MRI to confirm diagnosis, location, and extent of hemorrhage [Evidence Level A] 4, 2
- CTA, MRA, or catheter angiography to exclude underlying vascular lesions (aneurysms, arteriovenous malformations) [Evidence Level B] 4, 2
Essential Laboratory Tests
The actual laboratory evaluation should include 4:
- Coagulation studies: INR, PTT, platelet count [Evidence Level A]
- Medication history regarding anticoagulants and antiplatelets [Evidence Level C]
Clinical Assessment
- Neurological severity scoring (NIHSS for awake patients, GCS for obtunded patients) [Evidence Level B] 4, 2
- Blood pressure monitoring every 15 minutes until stabilized 4
Common Pitfall to Avoid
Do not confuse HLA testing (an immunology test for transplant matching) with the actual urgent needs in ICH management. The focus must be on rapid reversal of coagulopathy if present 3, blood pressure control 4, and preventing hematoma expansion 2—none of which involve HLA testing.
The question likely stems from confusion about what "HLA" means in this context, but there is no established role for human leukocyte antigen testing in cerebrovascular disease management.